Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine

被引:99
作者
Konishi, E [1 ]
Fujii, A [1 ]
机构
[1] Kobe Univ, Sch Med, Dept Hlth Sci, Suma Ku, Kobe, Hyogo 6540142, Japan
关键词
dengue; subunit vaccine; subviral particles;
D O I
10.1016/S0264-410X(01)00446-7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A dengue subunit vaccine candidate was developed using a mammalian cell line continuously expressing subviral extracellular particles (EPs) of the New Guinea C (NGC) strain of dengue type 2 virus. The cell line, designated D cell line, maintained envelope (E) antigen production for at least 10 passages. The EPs contained an E protein biochemically and antigenically equivalent to authentic E produced by NGC-infected Vero cells. Two immunizations of BALB/c mice with purified EPs containing 100 ng or 400 ng of E induced moderate levels of neutralizing antibody and anamnestic neutralizing antibody responses were produced when these animals were challenged with L dengue virus. The yield of E antigen from D cells was comparable to that from NGC-infected Vero cells. When D cells were transfected with the anti-apoptotic bcl-2 gene, the E antigen release increased approximately two-fold. These results indicate that D cell EPs are a promising non-infectious vaccine antigen for dengue. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1058 / 1067
页数:10
相关论文
共 63 条
[1]   SYNTHESIS AND SECRETION OF RECOMBINANT TICK-BORNE ENCEPHALITIS-VIRUS PROTEIN-E IN SOLUBLE AND PARTICULATE FORM [J].
ALLISON, SL ;
STADLER, K ;
MANDL, CW ;
KUNZ, C ;
HEINZ, FX .
JOURNAL OF VIROLOGY, 1995, 69 (09) :5816-5820
[2]   Development of a novel mouse model for dengue virus infection [J].
An, J ;
Kimura-Kuroda, J ;
Hirabayashi, Y ;
Yasui, K .
VIROLOGY, 1999, 263 (01) :70-77
[3]   Over a decade of experience with a yeast recombinant hepatitis B vaccine [J].
Assad, S ;
Francis, A .
VACCINE, 1999, 18 (1-2) :57-67
[4]  
Avirutnan P, 1998, J IMMUNOL, V161, P6338
[5]   Live attenuated tetravalent dengue vaccine [J].
Bhamarapravati, N ;
Sutee, Y .
VACCINE, 2000, 18 :44-47
[6]   Analysis of a recombinant dengue-2 virus dengue-3 virus hybrid envelope protein expressed in a secretory baculovirus system [J].
BielefeldtOhmann, H ;
Beasley, DWC ;
Fitzpatrick, DR ;
Aaskov, JG .
JOURNAL OF GENERAL VIROLOGY, 1997, 78 :2723-2733
[7]   PRODUCTION AND CHARACTERIZATION OF ARBOVIRUS ANTIBODY IN MOUSE ASCITIC FLUID [J].
BRANDT, WE ;
BUESCHER, EL ;
HETRICK, FM .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1967, 16 (03) :339-&
[8]   FLAVIVIRUS GENOME ORGANIZATION, EXPRESSION, AND REPLICATION [J].
CHAMBERS, TJ ;
HAHN, CS ;
GALLER, R ;
RICE, CM .
ANNUAL REVIEW OF MICROBIOLOGY, 1990, 44 :649-688
[9]   TECHNIQUES FOR HEMAGGLUTINATION AND HEMAGGLUTINATION-INHIBITION WITH ARTHROPOD-BORNE VIRUSES [J].
CLARKE, DH ;
CASALS, J .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1958, 7 (05) :561-573
[10]   West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays [J].
Davis, BS ;
Chang, GJJ ;
Cropp, B ;
Roehrig, JT ;
Martin, DA ;
Mitchell, CJ ;
Bowen, R ;
Bunning, ML .
JOURNAL OF VIROLOGY, 2001, 75 (09) :4040-4047